DrugDashboards

Piperacillin and Tazobactam

Piperacillin Sodium and Tazobactam Sodium · PIPERACILLIN SODIUM 2 g/1; TAZOBACTAM SODIUM .25 g/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Eugia US LLC

NDC 55150-0119-09 · 10 VIAL in 1 BOX / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. One of its named manufacturing plants, Aurobindo Pharma Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for piperacillin sodium and tazobactam sodium (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA065498
TE code
AP
Approval date
May 23, 2011
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Piperacillin Sodium and Tazobactam Sodium (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Eugia US LLCPIPERACILLIN SODIUM 4 g/1; TAZOBACTAM SODIUM .5 g/1Jul 15, 2026Sep 3, 2026
Eugia US LLCPIPERACILLIN SODIUM 2 g/1; TAZOBACTAM SODIUM .25 g/1Jul 15, 2026Sep 3, 2026
Eugia US LLCPIPERACILLIN SODIUM 36 g/250mL; TAZOBACTAM SODIUM 4.5 g/250mLJul 15, 2026Sep 2, 2026
Eugia US LLCPIPERACILLIN SODIUM 12 g/100mL; TAZOBACTAM SODIUM 1.5 g/100mLJul 15, 2026Sep 2, 2026
Mitim S.r.l.PIPERACILLIN SODIUM 3 g/15mL; TAZOBACTAM SODIUM .375 g/15mLJul 15, 2026Sep 2, 2026
Mitim S.r.l.PIPERACILLIN SODIUM 4 g/20mL; TAZOBACTAM SODIUM .5 g/20mLJul 15, 2026Sep 2, 2026
Mitim S.r.l.PIPERACILLIN SODIUM 2 g/10mL; TAZOBACTAM SODIUM .25 g/10mLJul 15, 2026Sep 2, 2026
Provepharm Inc.PIPERACILLIN SODIUM 4 g/20mL; TAZOBACTAM SODIUM .5 g/20mLJul 15, 2026Sep 2, 2026
Provepharm Inc.PIPERACILLIN SODIUM 12 g/60mL; TAZOBACTAM SODIUM 1.5 g/60mLJul 15, 2026Sep 2, 2026
Provepharm Inc.PIPERACILLIN SODIUM 2 g/10mL; TAZOBACTAM SODIUM .25 g/10mLJul 15, 2026Sep 2, 2026
Provepharm Inc.PIPERACILLIN SODIUM 3 g/15mL; TAZOBACTAM SODIUM .375 g/15mLJul 15, 2026Sep 2, 2026
Provepharm Inc.PIPERACILLIN SODIUM 36 g/180mL; TAZOBACTAM SODIUM 4.5 g/180mLJul 15, 2026Sep 2, 2026
Eugia US LLCPIPERACILLIN SODIUM 3 g/1; TAZOBACTAM SODIUM .375 g/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Piperacillin and Tazobactam — NDC 55150-0119-09," retrieved September 3, 2026, https://drugdashboards.com/drug/55150011909.

Free to cite with attribution — see how the data is put together.